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Brain injuries caused by stroke are common and costly
in human and resource terms. The result of stroke is a
cascade of molecular and physiological derangement,
cell death, damage and inflammation in the brain. This,
together with infection, if present, commonly results in
patients having an increased temperature, which is
associated with worse outcome. The usual clinical goal
in stroke is therefore to reduce temperature to normal,
or below normal (hypothermia) to reduce swelling if
brain pressure is increased. However, research evidence
does not yet conclusively show whether or not cooling
patients after stroke improves their longer-term
outcome (reduces death and disability). It is possible
that complications of cooling outweigh the benefits.
Cooling therapy may reduce damage and potentially
improve outcome, and head cooling targets the site of
injury and may have fewer side effects than systemic
cooling, but the evidence base is unclear.the assumption that direct brain cooling has fewer side ef-The recent study by Poli and colleagues [1] is part of a
suite of iCOOL studies in ischaemic and haemorrhagic
stroke, conducted at Heidelberg and linked to EuroHYP-1
(European multicentre, randomised, phase III clinical trial
of therapeutic hypothermia plus best medical treatment
versus best medical treatment alone for acute ischaemic
stroke [2]). Altogether the studies tested four different
methods of inducing hypothermia for speed of brain cool-
ing, feasibility and safety. Rhinochill and the Sovika head
and neck cooling device [1] and cold infusions compared
with Rhinochill (Rhinochill, Wallisellen, Switzerland,
EU) (iCOOL 1 NCT01573117 [1]), EMCOOLS Flex.Pads
(EMCOOLS, Brucknerstrasse 6/7a, 1040 Vienna, Austria)* Correspondence: p.andrews@ed.ac.uk
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medium, for 12 months following its publicat
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unless otherwise stated.(iCOOL 2 NCT01584167) and EMCOOLS Brain.Pad
(EMCOOLS, Brucknerstrasse 6/7a, 1040 Vienna, Austria)
(iCOOL 3 NCT01584180). The methods of inducing
hypothermia that are now included in the protocol for
EuroHYP-1 are cold infusion (20 ml/kg 4°C isotonic so-
dium chloride or Ringer’s lactate over 30 to 60 minutes)
with optional use of EMCOOLs Brain.Pad [3].
There has been an ongoing quest for methods of
therapeutic cooling that reduce temperature rapidly, are
portable and easily instigated and/or have the least side
effects. Cold infusion as a method of inducing cooling
has most often been studied in cardiac arrest but is cur-
rently being used in clinical trials of therapeutic hypother-
mia in stroke (EuroHYP-1 [3]) and traumatic brain injury
(Eurotherm3235Trial [4] and POLAR (NCT00987688)).
The attraction is that it is a relatively low-tech, readily avail-
able, portable method, requiring only a means of keeping
the infusion fluid at 4°C. Direct brain cooling has a long
history but there are few randomised controlled trials and
most are of low quality [5]. One of the attractions has been
fects than systemic cooling but this has not been estab-
lished [5]. Various methods of nasopharyngeal cooling have
been reported in the literature [5], including Rhinochill and
nasal [6] and pharyngeal balloons [7]. Rhinochill has been
studied most (for example, [8]) and there is very limited
human data on the pharyngeal balloon device [7] or the
pharyngeal cooling system of Takeda. Springborg and col-
leagues [6] report the use of QuickCool nasal balloons in a
mixed group of hyperthermic brain-injured patients.
Temperature was measured in the oesophagus, bladder
and (in some patients) intracranially. The goal of normo-
thermia was not reliably achieved. As with Poli and col-
leagues [1], this research raises questions about bladder
temperature as a proxy for intracranial temperature.
Perfluorocarbons are costly and their use in Rhinochill
has been questioned on environmental grounds [9].Central Ltd. The licensee has exclusive rights to distribute this article, in any
ion. After this time, the article is available under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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tions Rhinochill may not have major environmental
impact, this nevertheless warrants consideration. Use
of Rhinochill requires patients to be intubated and is
contraindicated with base of skull fracture, which limits its
use in traumatic brain injury.
Recently another method of nasopharyngeal cooling
has been reported by Fontaine and colleagues [10], with
experimental evidence and a human case report. This
method uses adiabatic expansion of gas pressure; 1 L
compressed carbon dioxide delivered via a nasal cannula.
Temperature is reduced because as the gas expands the
pressure reduction transfers energy as work (very rapidly)
and not as heat, although in practice there is some heat
transfer as insulation is not perfect. Carbon dioxide is of
course also a greenhouse gas and using it in this way
requires patients to be intubated. Compressed air and
oxygen were tested experimentally as alternatives and
found to remove considerably less heat than carbon
dioxide, but in vivo temperature differences were not
significant. In their study, Poli and colleagues [1]
show very nicely how different sites of temperature
measurement reflect temperature change differently
using intravenous and nasopharyngeal cooling. Where
intracranial temperature is the key temperature of
interest, as it arguably is in stroke and traumatic
brain injury, their data show the importance of meas-
uring this. As yet, however, there does not seem to
be much appetite for targeting therapeutic cooling to
intracranial temperature - invasive measurement is
not clinically warranted in less severe stroke and trau-
matic brain injury - and core body temperature is the
usual feedback parameter. In this case Poli and col-
leagues’ data [1] strongly suggest oesophageal temperature
is the best proxy for intracranial temperature. One diffi-
culty with this site of measurement is that with longer-
term cooling, if drugs are given nasogastrically, this will
affect the temperature readings [11]. Another is having to
site both a nasogastric tube and an oesophageal tempe-
rature probe with attendant increased risk of sinusitis and
abrasions. There have been moves to produce a nasogas-
tric tube suitable for feeding/drug instillation, aspiration
and temperature measurement but to our knowledge such
a potentially useful device is not yet in commercial
production.
The authors are to be congratulated on their compre-
hensive measurement of temperature reduction efficacy
and clear presentation of data measured at multiple
sites. The challenge is to move from evidence of efficacy
(temperature reduction) to evidence of effectiveness and
improved patient outcomes.Competing interests
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